



1642

PATENT

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Assistant Commissioner for Patents, Washington, D.C. 20231 on July 23, 2002.

Catherine M. Peck 07/23/02
Catherine M. Peck Date

#3/I.D.S.

TECH CENTER 1000/2000

JUL 29 2002

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Serial No.: 10/068,067
Conf. No.: 7530
Filed: February 5, 2002
Examiner: not yet assigned
Group Art Unit: 1642
Applicants: Rothenberg et al.
Title: **REGULATION OF CCR3 EXPRESSION**
Atty Docket No.: CMC-153

Cincinnati, Ohio 45202

July 23, 2002

Commissioner for Patents
Washington, D.C. 20231

Sir:

INFORMATION DISCLOSURE STATEMENT

In accordance with the duty of candor and good faith which is imposed by Rule 56 (37 C.F.R. §1.56), the art listed on the attached form PTO-1449 is called to the attention of the U.S. Patent and Trademark Office in connection with the above identified patent application. Copies of the cited references are enclosed. No representation is made that the cited art is the only art or that the cited art represents the best art.

The Examiner is urged to consider the cited references and to make an independent decision with respect to their materiality.

Applicants do not believe that any fees are due in connection with this submission, as there has been no first Action to date. However, if any fees are deemed

necessary, the Commissioner may consider this to be a request for such and charge
any necessary fees to Deposit Account 23-3000.

Respectfully submitted,


WOOD, HERRON & EVANS, L.L.P.

BY Beverly A. Lyman
Beverly A. Lyman
Reg. No. 41,961

2700 Carew Tower
441 Vine Street
Cincinnati, OH 45202
(513) 241-2324
(513) 421-7269 (facsimile)
K:\CMC\153\IDS transmittal.wpd

#3/I.D.S.

Sheet 1 (A) of 7

SUBSTITUTE FORM PTO-1449
(MODIFIED)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
CMC/153SERIAL NO.
10/O68,067INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(37 CFR 1.94(b))

(Use several sheets if necessary)

APPLICANT
Marc E. Rothenberg et al.FILING DATE
February 5, 2002GROUP
1642

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A.A	6 4 0 3 7 8 2	06/11/02	Luster et al.	536	23.5	08/04/99
	A.B						
	A.C						
	A.D						
	A.E						
	A.F						
	A.G						
	A.H						
	A.I						
	A.J						
	A.K						

RECEIVED
 JUL 29 2002
 TECH CENTER 1600/2900

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

	DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	A.L					
	A.M					
	A.N					
	A.O					
	A.P					
	A.Q					

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

A.R	Amara et al., HIV Coreceptor Downregulation as Antiviral Principle: SDF-1a-dependent Internalization of the Chemokine Receptor CXCR4 Contributes to Inhibition of HIV Replication, J. Exp. Med., 186(1), July 7, 1997, 139-146.
A.S	Bertrand and Ponath, CCR3 Blockade as a New Therapy for Asthma, Exp. Opin. Invest. Drugs, 9(1), 2000, 43-52
A.T	Combadiere et al., Cloning and Functional Expression of a Human Eosinophil CC Chemokine Receptor, Journal of Biological Chemistry, 270(27), July 14, 1995, 16491-16494.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Substitute Disclosure Form (PTO-1449)

SUBSTITUTE FORM PTO-1449
(MODIFIED)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
CMC/153SERIAL NO.
10/O68,067INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

(37 CFR 1.98(b))

APPLICANT
Marc E. Rothenberg et al.FILING DATE
February 5, 2002GROUP
1642

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	B.A						
	B.B						
	B.C						
	B.D						
	B.E						
	B.F						
	B.G						
	B.H						
	B.I						
	B.J						
	B.K						

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	B.L						
	B.M						
	B.N						
	B.O						
	B.P						
	B.Q						

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

B.R	Combadiere et al., <u>Cloning and functional expression of a human eosinophil CC chemokine receptor</u> , J. Biol Chem. 270(18), 11034.
B.S	Daugherty et al., <u>Cloning, Expression, and Characterization of the Human Eosinophil Eotaxin Receptor</u> , J. Exp. Med., 183, May 1996, 2349-2354.
B.T	Forster et al., <u>Intracellular and Surface Expression of the HIV-1 Coreceptor CXCR4/Fusion on Various Leukocyte Subsets: Rapid Internalization and Recycling Upon Activation</u> , Journal of Immunology, 160 (1998) 1522-1531.

EXAMINER


DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Substitute Disclosure Form (PTO-1449)

RECEIVED

JUL 29 2002



SUBSTITUTE FORM PTO-1449
(MODIFIED)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
CMC/153SERIAL NO.
10/O68,067INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

(37 CFR 1.98(b))

APPLICANT
Marc E. Rothenberg et al.FILING DATE
February 5, 2002GROUP
1642

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	C.A						
	C.B						
	C.C						
	C.D						
	C.E						
	C.F						
	C.G						
	C.H						
	C.I						
	C.J						
	C.K						

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	C.L						
	C.M						
	C.N						
	C.O						
	C.P						
	C.Q						

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

C.R	Franci et al., <u>Phosphorylation by a G Protein-Coupled Kinase Inhibits Signaling and Promotes Internalization of the Monocyte Chemoattractant Protein-1 Receptor</u> , Journal of Immunology, 1996, 5606-5612.
C.S	Hansel et al., <u>An improved immunomagnetic procedure for the isolation of highly purified human blood eosinophils</u> , Journal of Immunological Methods, 145 (1991) 105-110.
C.T	Matthews et al., <u>Eotaxin is Required for the Baseline Level of Tissue Eosinophils</u> , Proc. Natl. Acad. Sci. USA: Immunology, 95, May 1998, 6273-6278

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered.
Include a copy of this form with next communication to applicant.

Substitute Disclosure Form (PTO-1449)



RECEIVED
JUL 29 2002
TECH CENTER 1600/2900

SUBSTITUTE FORM PTO-1449
(MODIFIED)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
CMC/153SERIAL NO.
10/O68,067INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

(37 CFR 1.98(b))

APPLICANT
Marc E. Rothenberg et al.FILING DATE
February 5, 2002GROUP
1642

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	D.A.						
	D.B.						
	D.C.						
	D.D.						
	D.E.						
	D.F.						
	D.G.						
	D.H.						
	D.I.						
	D.J.						
	D.K.						

RECEIVED
 JUL 23 2002
 TECH CENTER 1600/2000

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	D.L.						
	D.M.						
	D.N.						
	D.O.						
	D.P.						
	D.Q.						

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

D.R.	Mueller et al., <u>Activation of Protein Kinase C Enhances the Phosphorylation of the Type B Interleukin-8 Receptor and Stimulates Its Degradation in Non-hematopoietic Cells</u> , Journal of Biological Chemistry, 270(18), May 5, 1995, 10439-10448.
D.S.	Ponath et al., <u>Molecular Cloning and Characterization of a Human Eotaxin Receptor Expressed Selectively on Eosinophils</u> , J. Exp. Med., 183, June 1996, 2437-2448.
D.T.	Rothenberg, <u>Eosinophilia</u> , New England Journal of Medicine, 338, May 28, 1998, 1592-1600.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449
(MODIFIED)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
CMC/153SERIAL NO.
10/O68,067INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

(37 CFR 1.98(b))

APPLICANT
Marc E. Rothenberg et al.FILING DATE
February 5, 2002GROUP
1642

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	E.A.						
	E.B.						
	E.C.						
	E.D.						
	E.E.						
	E.F.						
	E.G.						
	E.H.						
	E.I.						
	E.J.						
	E.K.						

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	E.L.						
	E.M.						
	E.N.						
	E.O.						
	E.P.						
	E.Q.						

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)


	E.R.	Rothenberg et al., <u>Targeted Disruption of the Chemokine Eotaxin Partially Reduces Antigen-Induced Tissue Eosinophilia</u> , J. Exp. Med., 185(4) February 17, 1997, 785-790
	E.S.	Sallusto et al., <u>Selective Expression of the Eotaxin Receptor CCR3 by Human T Helper 2 Cells</u> , Science, 277(5334), September 26, 1997, 2005-2007.
	E.T.	Samanta et al., <u>Interleukin 8 (Monocyte-derived Neutrophil Chemotactic Factor) Dynamically Regulates Its Own Receptor Expression on Human Neutrophils</u> , Journal of Biological Chemistry, 265(1), Jan. 5, 1990, 183-189.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Substitute Disclosure Form (PTO-1449)

RECEIVED
JUL 29 2002
TECH CENTER 1600/2800

SUBSTITUTE FORM PTO-1449
(MODIFIED)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
CMC/153SERIAL NO.
10/O68,067INFORMATION DISCLOSURE
STATEMENT BY APPLICANTAPPLICANT
Marc E. Rothenberg et al.

(Use several sheets if necessary)

FILING DATE
February 5, 2002GROUP
1642

(37 CFR 1.98(b))

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	F.A.						
	F.B.						
	F.C.						
	F.D.						
	F.E.						
	F.F.						
	F.G.						
	F.H.						
	F.I.						
	F.J.						
	F.K.						

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	F.L.						
	F.M.						
	F.N.						
	F.O.						
	F.P.						
	F.Q.						

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

F.R.	Solari et al., <u>Receptor-mediated Endocytosis of CC-chemokines</u> , Journal of Biological Chemistry, 272(15), Apr. 11, 1997, 9617-9620.
F.S.	Uguccioni et al., <u>High Expression of the Chemokine Receptor CCR3 in Human Blood Basophils, Role in Activation by Eotaxin, MCP-4, and Other Chemokines</u> , J. Clin. Invest. 100(5), September 1997, 1137-1143.
F.T.	Uhing et al., <u>Differential Regulation of cAMP by Endogenous Versus Transfected Formylpeptide Chemoattractant Receptors: Implications for G1-Coupled Receptor Signaling</u> , Biochemical and Biophysical Research Communications, 183(3), Mar. 31, 1992, 1033-1039.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Substitute Disclosure Form (PTO-1449)

SUBSTITUTE FORM PTO-1449
(MODIFIED)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
CMC/153SERIAL NO.
10/O68,067INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

(37 CFR 1.98(b))

APPLICANT
Marc E. Rothenberg et al.FILING DATE
February 5, 2002GROUP
1642

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	G.A.						
	G.B.						
	G.C.						
	G.D.						
	G.E.						
	G.F.						
	G.G.						
	G.H.						
	G.I.						
	G.J.						
	G.K.						

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

	DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	G.L.					
	G.M.					
	G.N.					
	G.O.					
	G.P.					
	G.Q.					

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

G.R.	Zimmermann et al., <u>Analysis of the CC Chemokine Receptor 3 Gene Reveals a Complex 5' Exon Organization, a Functional Role for Untranslated Exon 1, and a Broadly Active Promoter with Eosinophil-Selective Elements</u> , Blood, 96(7), October 1, 2000, 2346-2354
G.S.	
G.T.	

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered.
Include a copy of this form with next communication to applicant.

Substitute Disclosure Form (PTO-1449)

RECEIVED
JUL 29 2002
TECH CENTER 1600/2900